Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.transci.2020.102875 http://scihub22266oqcxt.onion/10.1016/j.transci.2020.102875 32694043!7362821!32694043     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transfus+Apher+Sci 2020 ; 59 (5): 102875 Nephropedia Template TP {{tp|p=32694043|t=2020. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study |pdf=|usr=}}{{32694043}} gab.com Text Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study JO: Transfus Apher Sci http://www.kidney.de/pget.php?&tw=1&pmid=32694043 #FOAvip Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy. Twit Text FOAVip Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study ????Transfus Apher Sci http://www.kidney.de/pget.php?&tw=1&pmid=32694043 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32694043 #FOAvip English Wikipedia <ref>{{Cite pmid|32694043}}</ref> Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study #MMPMID32694043 Abolghasemi H; Eshghi P; Cheraghali AM; Imani Fooladi AA; Bolouki Moghaddam F; Imanizadeh S; Moeini Maleki M; Ranjkesh M; Rezapour M; Bahramifar A; Einollahi B; Hosseini MJ; Jafari NJ; Nikpouraghdam M; Sadri N; Tazik M; Sali S; Okati S; Askari E; Tabarsi P; Aslani J; Sharifipour E; Jarahzadeh MH; Khodakarim N; Salesi M; Jafari R; Shahverdi S Transfus Apher Sci 2020[Oct]; 59 (5): 102875 PMID32694043show ga Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/immunology/*therapy[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive/adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/immunology/physiology[MESH] |Treatment Outcome[MESH]Clinical efficacy of convalescent plasma for treatment of COVID-19 inf(epmc).pdf DeepDyve Pubget Overpricing